C ONSIDERABLE EFFORTS ARE underway to improve our understanding of autoimmune disorders and to identify the underlying failure in immune system regulation. The goal of these efforts is to develop specific treatments that downregulate deleterious autoimmune reactions without affecting normal immune surveillance. Most strategies focus on either re-establishing immune tolerance to autoantigens or suppressing T lymphocyte activity using immunosuppressive drugs, such as cyclosporin A, FK506 or rapamycin 1 . Such approaches, however, have their disadvantages. Tolerance induction requires the characterization of autoantigens involved at each stage of the autoimmune process. Immunosuppressive drug treatment is limited by the lack of antigen specificity, which results in general suppression of Tcell immune function. Furthermore, prolonged immunosuppressive therapy is often accompanied by adverse side effects, such as nephrotoxicity In the Zhou study, treatment of rodents with Bis VIII in vivo abrogated autoantigen-specific immune responses as well as autoimmunity in two different models of T cell-mediated autoimmune disease-experimental allergic encephalitis (a model of multiple sclerosis) and adjuvant arthritis. This indicates that accelerated induction of the suicide program in T cells can limit (auto)antigendriven immune responses and that modulating apoptosis is an important way of regulating the immune system.
What is the molecular target of Bis VIII? Bisindolylmaleimides are potent inhibitors of PKC, a family of molecules that is known to mediate anti-apoptotic effects in many cell types 4, 5 . This suggests that inactivation of PKC by Bis VIII is responsible for the sensitization of T cells to death receptor-induced apoptosis. However, many (but not all) PKC inhibitors exert such an effect, suggesting that either Bis VIII has additional targets or that only certain PKC isoforms are involved in blocking apoptosis. It is tempting to speculate that these PKC isoforms (which have yet to be identified) may promote resistance to 'death' receptor-induced apoptosis by activating signaling pathways that induce expression of anti-apoptotic genes (refs. 6,7). Alternatively, these PKC isoforms may promote phosphorylation of pre-existing anti-apoptotic molecules (such as Bcl-2) thus increasing the resistance of cells to apoptosis 8 . Zhou and co-workers have demonstrated the beneficial effect of Bis VIII for the prevention or attenuation of autoimmune disease in two experimental CD4 + T cell-mediated autoimmune disorders. However, their data indicate that immunopathological reactions that involve cytotoxic CD8 + T cells may also be attenuated by Bis VIII because this drug promotes TNFα-mediated apoptosis (an essential component of AICD in CD8 + T cells). The Zhou study demonstrates that the simple notion of enhancing immune regu-
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latory mechanisms, which already exist but are impaired in autoimmune disease, is effective. This approach does not require the identification of autoantigens because only activated T cells appear to be affected by Bis VIII treatment. Because undesirable T cell-mediated immune responses are the underlying cause of many other pathologies, one can envision that a similar strategy may prevent organ transplant rejection or graft-versus-host disease. Despite these promising findings, extensive research is still needed to define the limits of such a therapeutic approach. In clinical settings, autoimmune disease generally becomes evident with tissue destruction, which occurs long after the initial induction of autoimmune effector cells. Hence, this situation is fundamentally different from that in experimental systems where autoimmunity is treated at the onset of the initial autoimmune reaction, before there is clinical evidence of disease.
Bis VIII affects the survival of activated cells irrespective of their antigen-specificity and without disturbing the initial activation of naive T cells. Therefore, in contrast to currently available immunosuppressive drugs, Bis VIII should not paralyze the immune system but rather should target all autoantigen-specific and activated lymphocytes that emerge during the establishing of an autoimmune disorder. Mounting an immune response against infectious agents should still be possible, although the response may be limited because Bis VIII will decrease the half life of activated lymphocytes.
Despite the bright outlook for Bis VIII therapy, some words of caution are in order. Increasing the Fas-mediated apoptosis of autoreactive T cells and tumor cells that express Fas receptor is certainly a worthy goal but are there situations where accelerated induction of apoptosis may be deleterious? Although impairment of humoral and cellular immune responses may be minimal compared to the dramatic effects of immunosuppressive drugs, Bis VIII may induce certain cell types to undergo 'premature' apoptosis. Hepatocytes and intestinal epithelial cells are known to be highly susceptible to apoptosis following Fas or TNF receptor activation 9, 10 . Prolonged Bis VIII therapy may increase apoptotic cell loss in the liver and the intestine resulting in severe side effects. Furthermore, in light of recent observations that tumor cells fight off attacking T cells by inducing them to undergo Fas-mediated apoptosis, tumor infiltrating T cells may end up murdered killers following Bis VIII treatment 11 . Thus, apoptosis remains a double-edged sword. Nevertheless, even if the path to successful treatment of autoimmunity is full of pitfalls, without new approaches there will be no cure.
